NasdaqGS - Nasdaq Real Time Price USD

CVRx, Inc. (CVRX)

4.7700

-3.0100

(-38.69%)

At close: May 9 at 4:00:01 PM EDT

4.9200

+0.15

+(3.14%)

After hours: May 9 at 7:45:32 PM EDT

CVRx Inc (CVRX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Sales Force Realignment ...

CVRx Inc (CVRX) reports a 15% revenue increase but faces short-term disruptions due to sales team restructuring and seasonality impacts.

GuruFocus.com yesterday

CVRX
-38.69%
CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of 5.36% and 0.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Zacks 2 days ago

CVRX
-38.69%
CVRx: Q1 Earnings Snapshot

The Minneapolis-based company said it had a loss of 53 cents per share. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 56 cents per share.

Associated Press Finance 2 days ago

CVRX
-38.69%
CVRx Reports First Quarter 2025 Financial and Operating Results

MINNEAPOLIS, May 08, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the first quarter of 2025. Recent Highlights Total revenue for the first quarter 2025 was $12.3 million, an increase of 15% over the prior year quarterU.S. Heart Failure (HF) revenue

GlobeNewswire 2 days ago

CVRX
-38.69%
CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CVRx (CVRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 9 days ago

CVRX
-38.69%

RXST
CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

MINNEAPOLIS, April 24, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced that it plans to release first quarter 2025 financial and operating results after market close on Thursday, May 8, 2025. The Company will host a conference call to review its results at 4:30pm Eastern Time the same day. A live webcast of the investor conference call will be available online at the investor relations page of the Company’s website at ir.cvr

GlobeNewswire 16 days ago

CVRX
-38.69%
CVRx Reports Preliminary First Quarter 2025 Financial Results

First quarter revenue expected to be approximately $12.3 million, representing growth of approximately 15% over first quarter 2024MINNEAPOLIS, April 07, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited first quarter 2025 revenue results. “While we continue to make significant progress in driving adoption of Barostim, first quarter revenue fell short of our expectations,” said Kevin Hykes, Preside

GlobeNewswire last month

CVRX
-38.69%
Several Insiders Invested In CVRx Flagging Positive News

When a single insider purchases stock, it is typically not a major deal. However, when multiple insiders purchase...

Simply Wall St. last month

CVRX
-38.69%
CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

New real-world evidence presented at THT 2025 and published simultaneously in the Journal of Cardiac Failure (JCF) demonstrates large and statistically significant reductions in hospital visits and length of stay in patients with heart failure and reduced ejection fractionMINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Thera

GlobeNewswire 2 months ago

CVRX
-38.69%
CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

CVRx (CVRX) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks 2 months ago

CVRX
-38.69%
Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 25.8% in CVRx (CVRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Zacks 2 months ago

CVRX
-38.69%
CVRx Full Year 2024 Earnings: EPS Misses Expectations

CVRx ( NASDAQ:CVRX ) Full Year 2024 Results Key Financial Results Revenue: US$51.3m (up 31% from FY 2023). Net loss...

Simply Wall St. 3 months ago

CVRX
-38.69%
CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses

CVRx Inc (CVRX) reports a 36% revenue increase in Q4 2024, driven by US heart failure segment growth, despite a slight net loss and increased R&D expenses.

GuruFocus.com 3 months ago

CVRX
-38.69%
CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

CVRx (CVRX) delivered earnings and revenue surprises of -16.22% and 0.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 3 months ago

CVRX
-38.69%
CVRx: Q4 Earnings Snapshot

The average estimate of three analysts surveyed by Zacks Investment Research was for a loss of 37 cents per share. The medical device company posted revenue of $15.3 million in the period. For the year, the company reported a loss of $60 million, or $2.65 per share.

Associated Press Finance 3 months ago

CVRX
-38.69%
CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

MINNEAPOLIS, Feb. 04, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced its financial and operating results for the fourth quarter and full year of 2024. Recent Highlights Total revenue for the fourth quarter of 2024 was $15.3 million, an increase of 36% over the prior year quarterU.S. Heart Failure (HF) rev

GlobeNewswire 3 months ago

CVRX
-38.69%
Hologic (HOLX) Reports Next Week: Wall Street Expects Earnings Growth

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 months ago

HOLX

CVRX
-38.69%
CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

MINNEAPOLIS, Jan. 21, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing Barostim™, an innovative extravascular implantable neuromodulation device for patients with cardiovascular diseases, today announced that it plans to release fourth quarter 2024 financial and operating results after market close on Tuesday, February 4, 2025. The Company will host a conference call to review its resul

GlobeNewswire 3 months ago

CVRX
-38.69%
CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?

CVRx (CVRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks 3 months ago

CVRX
-38.69%
CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to be $51.1 million to $51.2 million, representing growth of 30%Fiscal 2025 revenue expected to be between $63.0 million and $65.0 million, representing growth of 23% to 27% MINNEAPOLIS, Jan. 13, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company, today announced certain preliminary unaudited fourth quarter and full year 20

GlobeNewswire 3 months ago

CVRX
-38.69%

Performance Overview

Return	CVRX	S&P 500 (^GSPC)
YTD	-62.35%	-3.77%
1-Year	-34.75%	+8.55%
3-Year	-8.97%	+41.81%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

CVRx, Inc. (CVRX)

CVRx Inc (CVRX) Q1 2025 Earnings Call Highlights: Revenue Growth Amid Sales Force Realignment ...

CVRx (CVRX) Reports Q1 Loss, Tops Revenue Estimates

CVRx: Q1 Earnings Snapshot

CVRx Reports First Quarter 2025 Financial and Operating Results

CVRx (CVRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

CVRx to Report First Quarter 2025 Financial and Operating Results and Host Conference Call on May 8, 2025

CVRx Reports Preliminary First Quarter 2025 Financial Results

Several Insiders Invested In CVRx Flagging Positive News

CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim

CVRx (CVRX) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

Wall Street Analysts Predict a 25.76% Upside in CVRx (CVRX): Here's What You Should Know

CVRx Full Year 2024 Earnings: EPS Misses Expectations

CVRx Inc (CVRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth Amidst Rising Expenses

CVRx (CVRX) Reports Q4 Loss, Tops Revenue Estimates

CVRx: Q4 Earnings Snapshot

CVRx Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Hologic (HOLX) Reports Next Week: Wall Street Expects Earnings Growth

CVRx to Report Fourth Quarter 2024 Financial and Operating Results and Host Conference Call on February 4, 2025

CVRx (CVRX) Expected to Beat Earnings Estimates: Should You Buy?

CVRx Reports Preliminary Fourth Quarter and Fiscal Year 2024 Financial Results and Issues Fiscal 2025 Guidance

Performance Overview